MarketPulse
T

$TOVX

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Theriva Biologics

Theriva Biologics Advances VCN-01 Pancreatic Cancer Program With Phase 3 FDA Approval

Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.
TOVXFDA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Globe Newswire

Small-Cap Biotech and Industrial Firms Rally on Strategic Acquisitions and Patent Filings

Small-cap biotech and industrial firms rallied on acquisitions and patent filings. Interactive Strength surged 40% after acquiring Ergatta, while biotech companies advanced through strategic initiatives and IP development.
KBLBTRNRTOVXELABbiotechcommercialization